Company News
- CTD Announces Home-Based Dosing of First Patient in US Extension Protocol of Clinical Trial using Intravenous Administration of Trappsol (R) Cyclo (TM) for Niemann-Pick Disease Type C
May 23, 2019, 8:00 AM EDT - CTD Announces Participation and Support for Upcoming Gathering of Patient-Support Organizations for Niemann-Pick Disease type C
May 16, 2019, 8:00 AM EDT - CTD Announces New Expanded Access Program in the United Kingdom using Trappsol(R) Cyclo(TM) Intravenously for Niemann-Pick Disease type C
May 10, 2019, 8:25 AM EDT - CTD Announces New Expanded Access Program in Taiwan using Trappsol Cyclo for Niemann-Pick Disease type C
May 7, 2019, 8:00 AM EDT - CTD Holdings Announces M. Flint Beal, MD Joins Scientific Advisory Board
Apr 15, 2019, 8:00 AM EDT - CTD Holdings Announces Plan to Launch Clinical Trial of Trappsol (R) Cyclo (TM) in Alzheimer's Disease
Mar 14, 2019, 8:00 AM EDT - CTD Holdings to Present at Webinar for Patients and Families on Initial Clinical Trial Data
Mar 8, 2019, 8:00 AM EST - CTD Holdings Announces Grant to U.S. Non-Profit Organization to Support Patient Participation in Informational Meetings with Regulators
Feb 28, 2019, 10:00 AM EST - CTD Announces Appointment of Sharon H. Hrynkow, PhD as Chief Scientific Officer
Feb 15, 2019, 10:04 AM EST - CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™ Provided Intravenously for Patients with Niemann-Pick Disease Type C
Feb 7, 2019, 8:00 AM EST
